Technical Analysis for CELG - Celgene Corporation
|Grade||Last Price||% Change||Price Change|
CELG closed up 0.05 percent on Friday, August 18, 2017, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Trend Table & Recent Alerts
|See historical CELG trend table...|
|Date||Alert Name||Type||% Chg|
|Aug 18||New Downtrend||Bearish||0.00%|
|Aug 18||Lower Bollinger Band Walk||Other||0.00%|
|Aug 17||Stochastic Reached Oversold||Other||0.05%|
|Aug 16||Fell Below 50 DMA||Bearish||-2.75%|
|Aug 16||MACD Bearish Centerline Cross||Bearish||-2.75%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CELG news...
|52 Week High||139.0|
|52 Week Low||96.93|
|200-Day Moving Average||122.3533|
|50-Day Moving Average||131.695|
|20-Day Moving Average||133.901|
|10-Day Moving Average||131.97|
|Average True Range||2.5227|
|Chandelier Exit (Long, 3 ATRs)||131.4319|
|Chandelier Exit (Short, 3 ATRs)||134.8381|
|Upper Bollinger Band||139.9798|
|Lower Bollinger Band||127.8222|
|Percent B (%b)||-0.01|
|MACD Signal Line||0.2587|